Progression of human osteosarcoma with altered ANT1/SLC25a4 expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) is a primary bone cancer common in children and adolescents.
• Bioinformatics identified Adenosine nucleotide translocator 1 (ANT1), encoded by SLC25A4, as potentially involved in OS development and progression.

Purpose of the Study:

• To investigate the expression levels of ANT1/SLC25A4 in clinical osteosarcoma specimens and cell lines.
• To evaluate the potential of ANT1/SLC25A4 as a prognostic biomarker for osteosarcoma.
• To elucidate the mechanistic role of ANT1/SLC25A4 in osteosarcoma pathogenesis.

Main Methods:

• Immunohistochemical (IHC) analysis of ANT1 expression in 63 human OS tissue sections.
• Genetic modification of OS cell lines (MG-63, HOS) for SLC25A4 overexpression or knockdown.
• In vitro assays (proliferation, scratch wound-healing, transwell invasion) to assess cellular behavior.
• Statistical analysis including ANOVA and bivariate correlation.

Main Results:

• Diminished ANT1 expression was observed in the majority of clinical OS specimens (48/63) compared to normal periosteal tissue.
• SLC25A4 knockdown in vitro significantly increased osteosarcoma cell proliferation.
• Conversely, SLC25A4 overexpression significantly inhibited osteosarcoma cell migration and invasion (p <0.05).

Conclusions:

• ANT1/SLC25A4 is frequently downregulated in clinical osteosarcoma.
• Restoration of ANT1/SLC25A4 suppresses aggressive cellular phenotypes in vitro, suggesting a tumor suppressor role.
• Further research is warranted to correlate SLC25A4 expression with patient survival and understand its molecular pathways in OS.